We use cookies for a better user experience. Read our Privacy Policy

I Agree

Porcine Vaccine Market

Porcine Vaccine Market (Disease Indication - Diarrhea, Swine Influenza, Arthritis, Bordatella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), and Porcine Circovirus Associated Disease (PCVAD); End User - Veterinary Hospitals and Hog/Pig Production Farms; Technology - Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, and DNA Vaccines) - North America Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

North America Porcine Vaccine Market: Snapshot

For several decades, vaccination has remained one of the most important interventions for disease prevention among humans and animals. In veterinary medicine, vaccination has proven to be a boon for animal health. Diseases such as diarrhoea, swine influenza, porcine reproductive and respiratory virus (PRRSV), porcine circovirus associated disease (PCVAD), have been greatly reduced from spreading endemic in several cases. Some diseases such as foot and mouth disease and cholera high fever in swines have been significantly eliminated in North America with the help of vaccination. 

The market for porcine vaccine in the region is expected to exhibit healthy growth in the next few years as well. The rising demand for meat and gelatin and concerns regarding the rising pace of occurrence of zoonotic diseases will be the key factors driving the market in the near future. Transparency Market Research estimates that the North America porcine vaccine market will expand at a 5.3% CAGR from 2016 to 2024. As a result, the market, which valued at US$540.9 mn in 2015, will rise to US$926.2 mn by 2024. 

Inactivated Vaccines to Remain Most Preferred

In terms of the technology used to develop vaccines, the North America porcine vaccines market has been segmented into inactivated vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines, DNA vaccines, and conjugate vaccines. Of these, the segment of inactivated vaccines dominated the market in 2015 and is expected to account for a 53.3% of the North America veterinary vaccine market in 2016. The segment is also expected to exhibit the most promising growth in the near future, expanding at a 6.7% CAGR over the period between 2016 and 2024. 

The segment of live attenuated vaccines will exhibit a strong 5.9% CAGR over the said period. Rise in the number of swine farms, rising prevalence of zoonotic disease, and increase in investments by key players are likely to drive the live attenuated vaccine segment. The DNA vaccine segment is projected to emerge as a high-growth segment owing to rise in demand and increase in R&D investments. DNA vaccines have shown excellent results in granting strong immunity against homologous infections and have a good score in terms of approval from regulatory bodies in the region. As a result, the demand for these vaccines is expected to rise at a healthy pace in the region over the forecast period. porcine vaccine marketU.S. Market to Continue to Account for Dominant Chunk in Sales

The North America porcine vaccine market has been examined for two countries in the region: the U.S. and Canada. The U.S. market for porcine vaccines accounted for a larger 63% share in the North America market in 2015. The U.S. porcine vaccine market is expected to exhibit the most lucrative 6.6% CAGR over the period between 2016 and 2024. Factors such as well-established infrastructure in immunological research, high concentration of key players, highly organized farming structure, increased demand for animal protein, and rising expenditure on animal health by farm owners are attributed to the dominant share of the country in the North America market. 

The market in Canada is also anticipated to expand at a healthy, but comparatively lower CAGR of 5.8% from 2016 to 2024. Factors such as the rising prevalence of PRRS virus and PCV2 among herds and rising focus of key players on R&D activities for the development of effective vaccines will contribute to the growth prospects of the Canada porcine vaccines market in the near future. Moreover, export and import permits among contract manufacturers or distributer firms and low estimated cost of products are also expected to make the porcine vaccine market more popular in Canada. 

Some of the key players in the market are Bayer AG., Bimeda Animal Health, Boehringer Ingelheim GmbH, Ceva Santé Animale, Merck & Co., Inc., Merial (Sanofi), Vetoquinol, Zoetis, Inc., Elanco (Eli Lilly and Company). 

Porcine Vaccine Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : North America Porcine Vaccine Market

4. Market Overview
     4.1. Introduction
            4.1.1. Disease Indication Definition
            4.1.2. Industry Evolution / Developments
     4.2.  Overview
     4.3. Key Market Indicators
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
     4.5. North America Porcine Vaccine Market Analysis and Forecasts, 2014–2024
     4.6. Porter’s Five Force Analysis
     4.7.Regulations of Veterinary Vaccine in North America

5. North America Porcine Vaccine Market Analysis and Forecasts, By Disease Indication 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends
     5.4. Market Value Share Analysis Forecast By Disease Indication , 2014–2024
            5.4.1. Diarrhoea
            5.4.2. Swine Influenza
            5.4.3. Arthritis
            5.4.4. Bordatella Rhinitis
            5.4.5. Porcine Reproductive and Respiratory Virus (PRRSV)
            5.4.6. Porcine Circovirus Associated Disease (PCVAD)
            5.4.7. Others 
     5.5. Disease Indication  Comparison Matrix
     5.6. Market Attractiveness By Disease Indication 

6. North America Porcine Vaccine Market Analysis and Forecasts, By Technology
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market Value Share Analysis Forecast By Technology , 2014–2024
            6.4.1. Inactivated Vaccines
            6.4.2. Live Attenuated Vaccines
            6.4.3. Toxoid Vaccines
            6.4.4. Recombinant Vaccines
            6.4.5. Conjugate Vaccines
            6.4.6. DNA Vaccines
     6.6. Market Attractiveness By Technology

7. North America Porcine Vaccine Market Analysis and Forecasts, By End-user 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Key Trends
     7.4. Market Value Share Analysis Forecast By End-user , 2014–2024
            7.4.1. Veterinary Hospitals
            7.4.2. Hog/Pig Production Farm
     7.5. End-user  Comparison Matrix
     7.6. Market Attractiveness By End-user 

8. North America Porcine Vaccine Market Analysis and Forecasts, By Region
     8.1. Key Findings
     8.2. Policies and Regulations
     8.3. Market Value Share Analysis Forecast By Region
     8.4. Market Attractiveness By Country/Region

9. U.S. Porcine Vaccine Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
            9.1.2. Policies and Regulations
            9.1.3. Key Trends
     9.2. Market Value Share Analysis Forecast By Disease Indication , 2014–2024
            9.2.1. Diarrhoea
            9.2.2. Swine Influenza
            9.2.3. Arthritis
            9.2.4. Bordatella Rhinitis
            9.2.5. Porcine Reproductive and Respiratory Virus (PRRSV)
            9.2.6. Porcine Circovirus Associated Disease (PCVAD)
            9.2.7. Others 
     9.3. Market Value Share Analysis Forecast By Technology, 2014–2024
            9.3.1. Inactivated Vaccines
            9.3.2. Live Attenuated Vaccines
            9.3.3. Toxoid Vaccines
            9.3.4. Recombinant Vaccines
            9.3.5. Conjugate Vaccines
            9.3.6. DNA Vaccines
     9.4. Market Value Share Analysis Forecast By End-user, 2014–2024
            9.4.1. Veterinary Hospitals
            9.4.2. Hog/Pig Production Farm
     9.5. Market Value Share Analysis Forecast By Country , 2014–2024
     9.6. Market Attractiveness Analysis 
            9.6.1. By Disease Indication 
            9.6.2. By End-user 
            9.6.3. By Technology 
            9.6.4. By Country

10. Canada Porcine Vaccine Market Analysis and Forecast
     10.1.Introduction
            10.1.1. Key Findings
            10.1.2. Policies and Regulations
            10.1.3. Key Trends
     10.2.Market Value Share Analysis Forecast By Disease Indication , 2014–2024
            10.2.1. Diarrhoea
            10.2.2. Swine Influenza
            10.2.3. Arthritis
            10.2.4. Bordatella Rhinitis
            10.2.5. Porcine Reproductive and Respiratory Virus (PRRSV)
            10.2.6. Porcine Circovirus Associated Disease (PCVAD)
            10.2.7. Others 
     10.3.Market Value Share Analysis Forecast By Technology , 2014–2024
            10.3.1. Inactivated Vaccines
            10.3.2. Live Attenuated Vaccines
            10.3.3. Toxoid Vaccines
            10.3.4. Recombinant Vaccines
            10.3.5. Conjugate Vaccines
            10.3.6. DNA Vaccines
     10.4.Market Value Share Analysis Forecast By End-user , 2014–2024
            10.4.1. Veterinary Hospitals
            10.4.2. Hog/Pig Production Farm
     10.5.Market Value Share Analysis Forecast By Country , 2014–2024
     10.6.Market Attractiveness Analysis 
            10.6.1. By Disease Indication 
            10.6.2. By End-user 
            10.6.3. By Technology 
            10.6.4. By Country

11. Competition Landscape
     11.1.Market Player – Competition Matrix
     11.2.Market Share Analysis By Company (2016) Estimated
     11.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            11.3.1. Bayer AG.
                       11.3.1.1. Overview
                       11.3.1.2. Financials
                       11.3.1.3. Recent Developments
                       11.3.1.4. Strategy
            11.3.2. Bimeda Animal Health 
                       11.3.2.1. Overview
                       11.3.2.2. Financials
                       11.3.2.3. Recent Developments
                       11.3.2.4. Strategy
            11.3.3. Boehringer Ingelheim GmbH 
                       11.3.3.1. Overview
                       11.3.3.2. Financials
                       11.3.3.3. Recent Developments
                       11.3.3.4. Strategy
            11.3.4. Ceva Santé Animale
                       11.3.4.1. Overview
                       11.3.4.2. Financials
                       11.3.4.3. Recent Developments
                       11.3.4.4. Strategy 
            11.3.5. Elanco (Eli Lilly and Company)
                       11.3.5.1. Overview
                       11.3.5.2. Financials
                       11.3.5.3. Recent Developments
                       11.3.5.4. Strategy
            11.3.6. Merck & Co., Inc.
                       11.3.6.1. Overview
                       11.3.6.2. Financials
                       11.3.6.3. Recent Developments
                       11.3.6.4. Strategy 
            11.3.7. Merial (Sanofi)
                       11.3.7.1. Overview
                       11.3.7.2. Financials
                       11.3.7.3. Recent Developments
                       11.3.7.4. Strategy
            11.3.8. Vetoquinol
                       11.3.8.1. Overview
                       11.3.8.2. Financials
                       11.3.8.3. Recent Developments
                       11.3.8.4. Strategy
            11.3.9. Zoetis, Inc.
                       11.3.9.1. Overview
                       11.3.9.2. Financials
                       11.3.9.3. Recent Developments
                       11.3.9.4. Strategy
            11.3.10. Others

List of Tables

Table 1: North America Porcine vaccine Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 2: North America Porcine vaccine Market Size (US$ Mn) Forecast, by Technology, 2014–2024
Table 3: North America Porcine vaccine Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 4: North America Porcine vaccine Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 5: U.S. Porcine vaccine Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 6: U.S. Porcine vaccine Market Size (US$ Mn) Forecast, by Technology, 2014–2024
Table 7: U.S. Porcine vaccine Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 8: Canada Porcine Vaccine Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 9: Canada Porcine Vaccine Market Size (US$ Mn) Forecast, by Technology, 2014–2024
Table 10 Canada Porcine Vaccine Market Size (US$ Mn) Forecast, by End-user, 2014–2024

 

List of Figures

FIG 1: North America Porcine Vaccine Market Size (US$ Mn) Forecast, 2014–2024
FIG 2: Market Value Share, by Disease Indication
FIG 3: Market Value Share, by Technology
FIG 4: Market Value Share, by Country
FIG 5: Market Value Share, by End-user
FIG 6: North America Porcine vaccine Market Value Share Analysis, by Disease Indication, 2016 and 2024
FIG 7: North America Diarrhea Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
FIG 8: North America Swine Influenza Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
FIG 9: North America Arthritis Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
FIG 10: North America Bordatella Rhinitis Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
FIG 11: North America PRRSV Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
FIG 12: North America PCVAD Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
FIG 13: North America Other Disease Indication Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
FIG 14: North America Porcine vaccine Market Attractiveness Analysis, by Disease Indication, 2016–2024
FIG 15: North America Porcine vaccine Market Value Share Analysis, by Technology, 2016 and 2024
FIG 16: North America Inactivated vaccine Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2014–2024
FIG 17: North America Live Attenuated vaccine Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 
2014–2024
FIG 18: North America Toxoid vaccine Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2014–2024
FIG 19: North America Recombinant vaccine Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 
2014–2024
FIG 20: North America Conjugate vaccine Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2014–2024
FIG 21: North America DNA vaccine Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2014–2024
FIG 22: North America Porcine vaccine Market Attractiveness Analysis, by Technology, 2016–2024
FIG 23: North America Porcine vaccine Market Value Share Analysis, By End-user, 2016 and 2024
FIG 24: North America Veterinary Hospitals Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2014–2024
FIG 25: North America Hog/Pig Production Farms Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 
2014–2024
FIG 26: North America Porcine vaccine Market Attractiveness Analysis, by End-user, 2016–2024
FIG 27: North America Porcine vaccine Market Value Share Analysis, by Country, 2016 and 2024
FIG 28: North America Porcine Vaccine Market Attractiveness Analysis, by Country, 2016–2024
FIG 29: U.S. Porcine Vaccine Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2014–2024
FIG 30: U.S. Porcine vaccine Market Value Share Analysis, by Disease Indication, 2016 and 2024
FIG 31: U.S. Porcine vaccine Market Value Share Analysis, by Technology, 2016 and 2024
FIG 32: U.S. Porcine vaccine Market Value Share Analysis, by End-user, 2016 and 2024
FIG 33: U.S. Market Attractiveness Analysis, by Disease Indication, 2016–2024
FIG 34: U.S. Market Attractiveness Analysis, by Technology, 2016–2024
FIG 35: U.S. Market Attractiveness Analysis, by End-user, 2016–2024
FIG 36: Canada Porcine Vaccine Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2014–2024
FIG 37: Canada Porcine Vaccine Market Value Share Analysis, by Disease Indication, 2016 and 2024
FIG 38: Canada Porcine Vaccine Market Value Share Analysis, by Technology, 2016 and 2024
FIG 39: Canada Porcine Vaccine Market Value Share Analysis, by End-user, 2016 and 2024
FIG 40: Canada Porcine Vaccine Market Attractiveness Analysis, by Disease Indication, 2016–2024
FIG 41: Canada Porcine Vaccine Market Attractiveness Analysis, by Technology, 2016–2024
FIG 42: Canada Porcine Vaccine Market Attractiveness Analysis, by End-user, 2016–2024
FIG 43: North America Porcine Vaccine Market Share Analysis, by Company (2015)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

632

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved